Validation of a specific quality of life questionnaire for functional digestive disorders

Chassany, Olivier; Marquis, Patrick; Scherrer, Bruno; Read, N W; Finger, Thomas E.; Bergmann, Jean‐François; Fraitag, B; Genève, Jean; Caulin, C

doi:10.1136/gut.44.4.527

Cited by 156 publications

(106 citation statements)

References 28 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Disorders-Quality of Life (PAGI-QOL) 242 • Functional Digestive Disorders Quality of Life Questionnaire (FDDQL) 243 • Nepean Dyspepsia Index (NDI) 227 • Impact on day-to-day activity scale 224 • Glasgow Dyspepsia Severity Score 244 • Quality of Life in Reflux and Dyspepsia Questionnaire (QOLRAD) 245 • Gastrointestinal Quality of Life Index (GIQLI) 246 QOL, quality of life. …”

Section: Box 5 | Qol Instruments For Functional Dyspepsiamentioning

confidence: 99%

Functional dyspepsia

Enck¹,

Azpiroz

Boeckxstaens

et al. 2017

Nat Rev Dis Primers

253

247

View full text Add to dashboard Cite

| Functional dyspepsia is one of the most prevalent functional gastrointestinal disorders. Functional dyspepsia comprises three subtypes with presumed different pathophysiology and aetiology: postprandial distress syndrome (PDS), epigastric pain syndrome (EPS) and a subtype with overlapping PDS and EPS features. Functional dyspepsia symptoms can be caused by disturbed gastric motility (for example, inadequate fundic accommodation or delayed gastric emptying), gastric sensation (for example, sensations associated with hypersensitivity to gas and bloating) or gastric and duodenal inflammation. A genetic predisposition is probable but less evident than in other functional gastrointestinal disorders, such as irritable bowel syndrome (IBS). Psychiatric comorbidity and psychopathological state and trait characteristics could also play a part, although they are not specific to functional dyspepsia and are less pronounced than in IBS. Possible differential diagnoses include Helicobacter pylori infection and peptic ulceration. Pharmacological therapy is mostly based on the subtype of functional dyspepsia, such as prokinetic and fundus-relaxing drugs for PDS and acid-suppressive drugs for EPS, whereas centrally active neuromodulators and herbal drugs play a minor part. Psychotherapy is effective only in a small subset of patients, whereas quality of life can be severely affected in nearly all patients. Future therapies might include novel compounds that attempt to treat the underlying gastric and duodenal inflammation. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17081 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .standard therapy for gastro -oesophageal reflux disease. Paediatric dyspeptic symptoms are being addressed in a separate classification effort 10 . This Primer covers functional dyspepsia in adults only, although we sporadically refer to paediatric functional dyspepsia when similarities exist. EpidemiologyThe population prevalence of functional dyspepsia is quite variable across the globe, with overall high numbers (10-40%) in Western countries and low numbers (5-30%) in Asia, independent of the respective functional dyspepsia definitions 11 . A large-scale health and nutrition survey from France 12 (which involved >35,000 people) identified that 15% of individuals had suspected functional dyspepsia, 28% had irritable bowel syndrome (IBS) and 6% had both. The population of patients who are affected by both IBS and functional dyspepsia has been reported to range between 10% and 27% in previous studies 13 and to approach 30% in popu lation samples; it could be even higher in specific populations 14,15 . This observation has given rise to the term 'overlap syndrome' (REF. 13), which calls into question the sensitivity and specificity of the Rome criteria, at least for IBS and functional dyspepsia. This argument is also supported by the observation that patients with functional dyspepsia m...

show abstract

Section: Box 5 | Qol Instruments For Functional Dyspepsiamentioning

confidence: 99%

Functional dyspepsia

Enck¹,

Azpiroz

Boeckxstaens

et al. 2017

Nat Rev Dis Primers

253

247

View full text Add to dashboard Cite

show abstract

“…2,3,7,14 The clinical validity of the instrument has been tested on samples with a range of chronic disorders including low back pain, menorrhagia, suspected peptic ulcer, varicose veins, 3,15 asthma, 16 migraine, 17 HIV, Bensoussan et al Article post-operative functioning 19,20 , and more recently, functional digestive disorders. 21,22 This paper presents further validation of the SF36 in IBS patients and new evidence of its capacity to measure health change following intervention.…”

mentioning

confidence: 99%

Application of the general health status questionnaire SF36 to patients with gastrointestinal dysfunction: initial validation and validation as a measure of change

Bensoussan

Chang

Menzies

et al. 2001

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

Objective : To determine whether the Short Form (SF36) Health Status Survey is a valid measure of health status and health change for patients with irritable bowel syndrome (IBS). Methods : The SF36 was self‐administered by 116 patients with IBS at the commencement and end of a controlled clinical trial. Patients were recruited through two Sydney teaching hospitals and through private gastroenterologists during 1997 and treated with Chinese herbal medicine. Results : The SF36 health concepts demonstrated internal consistency, construct validity and concurrent validity when applied to patients with significant bowel dysfunction. Patient scores on two health scales of the SF36 (bodily pain, general health) correlated significantly with the bowel symptom scores recorded by patients and gastroenterologists at the beginning and end of the trial period. Actively treated patients significantly improved their scores in four out of eight of the health scales of the SF36 and reported overall improvement compared with inactively treated patients. Conclusions : The SF36 is a valid measure of general health status in IBS patients, is sensitive to the presence of IBS, and is adequately sensitive to gastrointestinal change in IBS patients. Implications : While the SF36 general health measure is used by the Australian Bureau of Statistics and widely overseas, until recently no data have been available on the sensitivity of the SF36 to gastrointestinal dysfunction or numerous other disorders. The SF36 is not only sensitive to the presence of IBS, it also provides a useful adjunct to current methods of evaluating treatment outcomes for IBS, and potentially other disorders.

show abstract

“…Diagnostic criteria for IBS used were as follows: ten trials used Rome II, two trials used Rome, and one trial used Manning. However, in Gade's study [18] [32]. Whorwell [30] and O'Mahony [27] used IBS specific quality of life questionnaire [33].…”

Section: Resultsmentioning

confidence: 99%

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

2010

Clinical Governance: An Intl J

View full text Add to dashboard Cite

show abstract

Validation of a specific quality of life questionnaire for functional digestive disorders

Cited by 156 publications

References 28 publications

Functional dyspepsia

Functional dyspepsia

Application of the general health status questionnaire SF36 to patients with gastrointestinal dysfunction: initial validation and validation as a measure of change

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

Contact Info

Product

Resources

About